0000000000266258

AUTHOR

Carlo Morosi

showing 8 related works from this author

Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-…

2016

11044Background: We already reported (Cancer 2012;118:5857) on better correlation of Choi criteria (Choi) than RECIST with the outcome of pts affected by high-risk STS entering a multicentric Itali...

Cancer Researchmedicine.medical_specialtyChemotherapybusiness.industry10 year follow upSoft tissue sarcomamedicine.medical_treatmentCancerExploratory analysismedicine.diseaseTumor response030218 nuclear medicine & medical imagingSurgery03 medical and health sciences0302 clinical medicineOncologyChoi Criteria030220 oncology & carcinogenesismedicineRadiologybusinessJournal of Clinical Oncology
researchProduct

Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

2012

BACKGROUND. The objective of this study was to compare the prognostic relevance of Response Evaluation Criteria in Solid Tumors (RECIST) versus Choi criteria for the assessment of response in patients with high-risk soft tissue sarcoma of the extremities or trunk wall who received preoperative chemotherapy with or without radiotherapy in a phase 3 trial. METHODS. Patients received 3 cycles of preoperative epirubicin þ ifosfamide with or without radiotherapy. The diagnostic concordance between RECIST and Choi criteria and their correlation with overall survival (OS) and freedom from progression (FFP) were evaluated in a univariate Cox regression model. RESULTS. In 243 of 321 eligible patient…

RiskCancer Researchmedicine.medical_specialtymedicine.medical_treatmentchemotherapymedicineHumansResponse Evaluation Criteria in Solid TumorsProbabilityProportional Hazards ModelsRetrospective Studiesresponse assessmentIfosfamideProportional hazards modelbusiness.industrySoft tissue sarcomachemotherapy; Choi criteria; outcome; prognosis; response assessment; Response Evaluation Criteria in Solid Tumors; sarcoma; Cancer Research; OncologySarcomamedicine.diseasePrognosisSurgeryRadiation therapyChoi criteriaOncologyResponse Evaluation Criteria in Solid TumorsoutcomeRadiologySarcomabusinessProgressive diseasemedicine.drugEpirubicinCancer
researchProduct

Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding pat…

2018

11558Background: We already reported (Cancer 2012;118:5857) the correlation of Choi criteria (Choi) and RECIST with outcome of pts affected by high-risk STS entering a multicentric Italian/Spanish ...

OncologyCancer Researchmedicine.medical_specialtyChemotherapyIfosfamideAnthracyclinebusiness.industrymedicine.medical_treatmentCancerSoft tissueSubgroup analysismedicine.diseaselaw.inventionOncologyRandomized controlled triallawInternal medicinemedicinebusinessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from th…

2016

[Background] To report on long-term results of a phase 3 trial comparing three versus five cycles of adjuvant chemotherapy (CT) with full-dose epirubicin+ifosfamide in high-risk soft tissue sarcomas (STS).

LeiomyosarcomaMale0301 basic medicinesarcomaSurvivalmedicine.medical_treatment0302 clinical medicineRisk FactorsQuality of surgeryNeoadjuvant therapySoft tissue sarcomaIfosfamideresponseSoft tissue sarcomaResponseSarcomaHematologyMiddle AgedPrognosisadjuvant chemotherapyTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesissoft tissue sarcomaFemaleSarcomaadjuvant chemotherapy; quality of surgery; response; sarcoma; soft tissue sarcoma; survivalmedicine.drugEpirubicinAdultLeiomyosarcomamedicine.medical_specialtyPreoperative caresurvivalDisease-Free Survival03 medical and health sciencesmedicineHumansAgedbusiness.industrymedicine.diseaseSurgeryAdjuvant chemotherapyRegimen030104 developmental biologybusinessquality of surgeryFollow-Up Studies
researchProduct

Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network

2021

Background: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. Methods: Adult patients with a diagnosis of advanced, brachyury-positive chordoma, treated from April 2007 to October 2020 with wCDDP or wCDDP/I were retrospectively identified. Imatinib was withheld at the same time as wCDDP. Response according to Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS) were analyzed. Results: Thirty-three consecutive patients were identified (wCDDP as front-line n = 8 [24.2%]; wCDDP as…

AdultCancer Researchbone sarcomacisplatinsystemic treatmentchemotherapyDisease-Free SurvivalTreatment OutcomeOncologyimatinibImatinib MesylateHumansProspective StudieschordomaRetrospective Studies
researchProduct

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

2014

Abstract Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the …

Chemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sulfonamides; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2; Cancer Research; Oncology; Medicine (all)OncologyMaleCancer ResearchIndolesAxitinibPyridinesPyridinemedicine.medical_treatmentSolitary fibrous tumourAdministration OralAngiogenesis InhibitorsMice SCIDPharmacologyPyrroleAntineoplastic Agentchemistry.chemical_compoundMiceSolitary Fibrous TumorChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Cancer Research; Oncology; Medicine (all)Transplantation HeterologouMonoclonalSunitinibHumanizedSulfonamidesHeterologousSunitinibMedicine (all)ImidazolesSarcomaMiddle AgedSorafenibPlatelet-Derived Growth Factor betaAxitinibBevacizumabOncologySolitary Fibrous TumorsAdministrationAngiogenesis InhibitorHumanmedicine.drugReceptorPhenylurea CompoundSorafenibOralAdultNiacinamidemedicine.medical_specialtyIndazolesBevacizumabMAP Kinase Signaling SystemTransplantation HeterologousAntineoplastic AgentsSulfonamideAntibodies Monoclonal HumanizedSCIDAntibodiesReceptor Platelet-Derived Growth Factor betaPazopanibInternal medicineRegorafenibmedicineAnimalsHumansChemotherapyPyrrolesImidazoleTyrosine kinaseAgedChemotherapyTransplantationAnimalbusiness.industryPhenylurea CompoundsPazopanibmedicine.diseaseChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2IndazolePyrimidinesPyrimidinechemistryIndolebusinessProgressive diseaseNeoplasm Transplantation
researchProduct

Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.

2016

11042Background: The reported response rate to chemotherapy (CT) in SFT is low both with anthracycline-based regimens ( ≤ 20%) and with trabectedin ( < 10%). DTIC can be active. We report on the co...

OncologyCancer Researchmedicine.medical_specialtyChemotherapySolitary fibrous tumorSeries (stratigraphy)Anthracyclinebusiness.industrymedicine.medical_treatmentfungifood and beverages.medicine.diseaseOncologyInternal medicineMedicineDoxorubicinDacarbazine - DTICbusinessTrabectedinmedicine.drugJournal of Clinical Oncology
researchProduct

Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Netwo…

2021

Background This multicentric, retrospective study conducted within the Italian Rare Cancer Network describes clinical features and explores their possible prognostic relevance in patients with advanced epithelioid haemangioendothelioma (EHE) started on surveillance. Patients and methods We collected data on adult patients with molecularly confirmed, advanced EHE consecutively referred at five sarcoma reference centres between January 2010 and June 2018, with no evidence of progressive disease (PD) and started on surveillance. Overall survival (OS) and progression-free survival (PFS) univariable and multivariable Cox analyses were performed. In the latter, due to the low number of cases and …

AdultCancer Researchmedicine.medical_specialtyEpithelioid haemangioendotheliomaPopulationGastroenterologyepithelioid haemangioendotheliomaWeight lossInternal medicinemedicineHumanseducationResponse Evaluation Criteria in Solid TumorsRetrospective StudiesOriginal ResearchSeries (stratigraphy)education.field_of_studybusiness.industryprognostic factorsRetrospective cohort studymedicine.diseasePrognosisOncologyEffusionItalysurveillanceoutcomeHemangioendothelioma Epithelioidserosal effusionsymptomsSarcomamedicine.symptombusinessProgressive diseaseESMO open
researchProduct